医学
贫血
心力衰竭
缺铁
骨髓增生异常综合症
输血
慢性病贫血
冠状动脉疾病
输血疗法
心肌梗塞
重症监护医学
病因学
红细胞生成
内科学
骨髓
作者
Jeffrey L. Carson,Gary M. Brittenham
出处
期刊:Blood
[American Society of Hematology]
日期:2022-10-31
卷期号:142 (9): 777-785
被引量:5
标识
DOI:10.1182/blood.2022018521
摘要
Abstract Severe anemia is commonly treated with red blood cell transfusion. Clinical trials have demonstrated that a restrictive transfusion strategy of 7 to 8 g/dL is as safe as a liberal transfusion strategy of 9 to 10 g/dL in many clinical settings. Evidence is lacking for subgroups of patients, including those with preexisting coronary artery disease, acute myocardial infarction, congestive heart failure, and myelodysplastic neoplasms. We present 3 clinical vignettes that highlight the clinical challenges in caring for patients with coronary artery disease with gastrointestinal bleeding, congestive heart failure, or myelodysplastic neoplasms. We emphasize that transfusion practice should be guided by patient symptoms and preferences in conjunction with the patient’s hemoglobin concentration. Along with the transfusion decision, evaluation and management of the etiology of the anemia is essential. Iron-restricted erythropoiesis is a common cause of anemia severe enough to be considered for red blood cell transfusion but diagnosis and management of absolute iron deficiency anemia, the anemia of inflammation with functional iron deficiency, or their combination may be problematic. Intravenous iron therapy is generally the treatment of choice for absolute iron deficiency in patients with complex medical disorders, with or without coexisting functional iron deficiency.
科研通智能强力驱动
Strongly Powered by AbleSci AI